Compare BSM & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSM | AVDL |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2015 | 1996 |
| Metric | BSM | AVDL |
|---|---|---|
| Price | $14.15 | $21.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.00 | ★ $18.38 |
| AVG Volume (30 Days) | 402.2K | ★ 2.8M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 8.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $412,814,000.00 | $248,517,000.00 |
| Revenue This Year | $1.06 | $65.47 |
| Revenue Next Year | $10.27 | $30.88 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | ★ 79.88 |
| 52 Week Low | $11.78 | $6.38 |
| 52 Week High | $15.60 | $23.57 |
| Indicator | BSM | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 59.42 |
| Support Level | $14.31 | $21.34 |
| Resistance Level | $14.69 | $21.55 |
| Average True Range (ATR) | 0.27 | 0.24 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 43.44 | 13.46 |
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.